Cargando…
Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent
A program to identify novel intravenous sedatives with a short and predictable duration of action was initiated in the late 1990’s by Glaxo Wellcome. The program focussed on the identification of ester-based benzodiazepine derivatives that are rapidly broken down by esterases. Remimazolam was identi...
Autor principal: | Kilpatrick, Gavin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329483/ https://www.ncbi.nlm.nih.gov/pubmed/34354587 http://dx.doi.org/10.3389/fphar.2021.690875 |
Ejemplares similares
-
Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent
por: Kim, Seong-Hyop, et al.
Publicado: (2022) -
Remimazolam: An Updated Review of a New Sedative and Anaesthetic
por: Hu, Qinxue, et al.
Publicado: (2022) -
Remimazolam: The future of its sedative potential
por: Goudra, Basavana Gouda, et al.
Publicado: (2014) -
An anesthetic experience with remimazolam for MELAS patients
por: Kitaura, Atsuhiro, et al.
Publicado: (2022) -
Review of remimazolam and sedatives in the intensive care unit
por: Choi, Hey-Ran, et al.
Publicado: (2022)